Loading
A phase 1/2 trial of TUB-040 in ovarian cancer and non-small-cell lung cancer, run by Tubulis GmbH, now recruiting.
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC is a phase 1/2 interventional study registered as NCT06303505 by Tubulis GmbH, with 250 participants planned, started 2024-06-12 and due to reach its primary completion in 2027-12. Interventions recorded: TUB-040.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tubulis (Gilead), Ovarian cancer and the tag pipeline.
Shares Tubulis (Gilead), Non-small-cell lung cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/